Dr. Xianyong (Sean) Gui, MD, FCAP, FASCP is the primary pathology contact to represent AcelaBio’s pathology perspective. He is responsible for providing scientific and medical leadership for the development, validation, and operationalization of anatomic and molecular pathology services in the AcelaBio laboratory, including selection and design of assays to identify biomarkers for a drug or therapeutic indication. Sean also plays an important role in the review of clinical cases, including but not limited to disease activity scoring and diagnosis. He works closely with the Medical Laboratory Director to guide the laboratory operations at AcelaBio in accordance with organizational and industry best practices that meet regulatory requirements and guidelines.
Dr. Gui is a licensed physician and an anatomic/clinical pathologist certified by American Board of Pathology, with additional subspecialty credential in gastrointestinal (GI)-hepatobiliary-pancreatic pathology. He completed his pathology residency at the University of Illinois at Chicago and GI/liver pathology fellowship at the Mount Sinai School of Medicine in New York. He has been practicing in academic medical centers and serving on faculty at the University of Calgary (Alberta, Canada) and University of Washington (Seattle, USA) for more than 14 years. He remains to hold academic appointment as Clinical Professor of Pathology at both of these two institutions and continues to be a consultant pathologist performing diagnostic service and teaching pathology trainees. He was the inaugural Director of GI/Liver Pathology Service at the University of Calgary / Calgary Laboratory Services and served in that position for 6 years. Dr. Gui has extensive clinical and research experiences in both non-neoplastic and neoplastic GI/liver diseases, and he is particularly interested in the pathobiology and clinical-pathological correlation in the inflammatory bowel diseases (IBD). Prior to his pathology career, Dr. Gui also had postgraduate clinical training in gastroenterology as well as post-doctoral research experience in basic digestive science.
Dr. Gui has published more than 80 research articles. He received the “Basic Science Research Award (for clinical faculty)” from the Cumming School of Medicine in University of Calgary in 2013. He was instrumental to the development of PiCaSSO Histologic Remission Index (PHRI), a novel and simplified histologic score for assessing mucosal healing in ulcerative colitis, that was proposed in 2022 by an international group of gastroenterologists and GI pathologists in which Dr. Gui was the pathology lead.
“Sometimes, it is the people no one imagines anything of who do the things that no one can imagine.” – Alan Turin